<DOC>
	<DOCNO>NCT02653313</DOCNO>
	<brief_summary>Investigation safety , tolerability efficacy parvovirus H-1 ( ParvOryx ) subject suffer metastatic , inoperable pancreatic cancer least one hepatic metastasis .</brief_summary>
	<brief_title>Parvovirus H-1 ( ParvOryx ) Patients With Metastatic Inoperable Pancreatic Cancer</brief_title>
	<detailed_description>Investigation safety , tolerability efficacy parvovirus H-1 ( ParvOryx ) subject suffer metastatic , inoperable pancreatic cancer least one hepatic metastasis . Initially four equal dos ParvOryx administer intravenously four consecutive day . Seven fourteen day first intravenous administration drug inject directly hepatic metastasis pancreatic cancer .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Pancreatic Ductal</mesh_term>
	<criteria>1 . Age least 18 year , 2 . Ability give inform consent , 3 . Histologically confirm pancreatic ductal adenocarcinoma ( PAD ) least one measurable hepatic metastasis accord RECIST 1.1 , 4 . Disease progression despite first line therapy ( whatever chemotherapy regimen ) , 5 . Eligibility second line chemotherapy gemcitabine , 6 . ECOG performance scale 0 1 , 7 . Consent sample investigation biological specimen schedule trial protocol , 8 . Adequate bone marrow function : neutrophil &gt; 1.5 x 1E09/L , platelet &gt; 100 x 1E09/L , hemoglobin &gt; 9.0 g/dL , 9 . Liver function test ( LFT ) within follow range : Bilirubin &lt; 3 x ULN ( Upper Limit Normal ) ; ASAT ALAT &lt; 5 x ULN , 10 . Adequate renal function : Creatinine &lt; 1.5 g/dL , 11 . Adequate blood clotting : aPTT &lt; 39 sec , INR &lt; 1.2 , 12 . Normal thyroid function , i.e . TSH , fT3 fT4 within normal range ( TSH : 0.4 4.0 mU/l , fT3 : 2.0 4.2 ng/l , fT4 : 8 18 ng/l ) 13 . Negative serology HIV , HBV HCV , 14 . Negative BetaHCG test blood woman childbearing potential , 15 . Use adequate contraception gender , i.e . use doubleeffective method contraception entire participation trial . 1 . Eligibility surgical treatment , 2 . Symptomatic cerebral , pulmonal , and/or osseous metastasis , 3 . Peritoneal carcinosis , 4 . Liver cirrhosis , 5 . Splenectomy , 6 . Relevant respiratory impairment , correspond grade IV V MRC Breathlessness Scale ( stops breath walk 100 meter minute level ground , breathless leave house , breathless undress ) , 7 . Positive antidrug antibody ( ADAs ) ParvOryx , 8 . Hospitalization due condition pancreatic cancer within last 3 month , 9 . Chemotherapy within 2 week prior first administration IMP , 10 . Signs active , systemic infection within 7 day prior study inclusion ( clinical symptom ( cough , run nose , burn sensation urinating , apparent skin wound infection ) and/or increase fever and/or deterioration infectionspecific laboratory parameter beyond change apparently drive underlying pancreatic cancer ) , 11 . Radiotherapy within 6 week prior study inclusion , 12 . Contraindications CT , 13 . Known allergy iodinate contrast medium , 14 . Participation another interventional trial within last 30 day , 15 . Presumed contact pregnant woman and/or infant &lt; 12 month age within two month first administration IMP .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>